TAVI NEWS WEEKLY — 2 Nov 2026

1. What changed this week

[Edwards] EARLY TAVR economic analysis (TCT 2026, 1 Nov): in 901 patients with asymptomatic severe AS, 5-year cumulative costs were similar for early TAVI and clinical surveillance ($86,572 vs $85,044; P=0.60). Over a lifetime, early TAVI was projected to add about $4,500 and 0.3 QALYs, an ICER of $14,698 per QALY (91.3% probability of being cost-effective, US perspective). By 5 years, 95% of the surveillance arm had undergone TAVI.

Source:

https://www.tctmd.com/news/early-tavr-economic-analysis-supports-tavi-over-clinical-surveillance-asymptomatic

[MDT] Medtronic presented the EXPAND TAVR II design and baseline characteristics at TCT (31 Oct): 692 patients with moderate AS randomised at 96 sites in 16 countries to Evolut TAVR plus GDMT vs GDMT alone; mean age 78.4, 42.3% female. No outcomes yet; Evolut in moderate AS is investigational.

Source:

https://news.medtronic.com/Medtronic-presents-Evolut-EXPAND-TAVR-II-trial-design-and-baseline-characteristics-of-patients-with-moderate-aortic-stenosis-at-TCT-2026

[Other] SEASON-AR (TCT, 31 Oct; Circulation): in 210 patients with severe pure AR at high surgical risk or declining SAVR (18 Chinese centres), transfemoral TAVI plus GDMT cut 1-year death, disabling stroke or HF rehospitalisation vs GDMT alone (8.3% vs 24.8%; HR 0.31), mainly through fewer HF admissions. Major bleeding (9.2% vs 0) and new pacemakers (20.2% vs 2.0%) were higher with TAVI.

Source:

https://www.tctmd.com/news/tavi-plus-gdmt-suitable-select-patients-severe-aortic-regurgitation

[Abbott] Abbott's investigational balloon-expandable BE TAVI early feasibility study was presented by Dr Susheel Kodali at TCT (1 Nov). ClinicalTrials.gov lists 11 patients enrolled; no public results yet. Investigational device, limited by US law to investigational use.

Source:

https://www.tctmd.com/slide/novel-balloon-expandable-transcatheter-heart-valve-aortic-stenosis-be-tavi-early-feasibility

[Market] Still to come at TCT: PROGRESS (SAPIEN 3 TAVI vs surveillance in moderate AS) and CLASP II TR today (2 Nov); DUOTAP, JENA-VAD, PROTEMBO IDE, SINGLE-CLOSURE and ENCIRCLE 2-year on 3 Nov. Edwards reports Q3 on 4 Nov.

Source:

https://www.tctconference.com/late-breaking-clinical-trials-science

2. Papers / congress abstracts to read

[Abbott] Kemp, Navitor IDE 5-year update, TCT-1030 (JACC supplement, online 31 Oct; presented 2 Nov).

Source:

https://www.jacc.org/doi/10.1016/j.jacc.2026.09.1242

[Other] TCT 512 and 513 (1 Nov): modelling of TAVR oversizing against pacemaker and annular-rupture risk, and annular oversizing with supra-annular self-expanding valves.

Source:

https://www.tctmd.com/slide/tct-512-continuous-rcs-modeling-tavr-oversizing-mapping-non-linear-dose-response-between

[Other] Van Mieghem, "State of the Data: From UNLOAD to PROGRESS and EXPAND TAVR II" (TCT, 1 Nov), a primer on the moderate-AS trials.

Source:

https://www.tctmd.com/slide/state-data-unload-progress-and-expand-tavr-ii

3. New Devices in Cardiology and Structural Heart

[Other] Meril gave a technology and programme update on its MyValve Octocor TAVR system at TCT (1 Nov).

Source:

https://www.tctmd.com/slide/myvalve-octocor-tavr-system-technology-and-program-update

[Other] TRAVEL III (TCT, 1 Nov): LuX-Valve Plus transcatheter tricuspid replacement vs medical therapy in 118 high-risk severe TR patients; 98.7% procedural success, and 93.2% had moderate or less TR at 6 months.

Source:

https://www.acc.org/latest-in-cardiology/articles/2026/11/01/00/11/sun-551pm-combo2-tct-2026

4. Advances in Cardiology and Structural Heart Tech

[Other] P4 (TCT, 1 Nov; NEJM): CCTA-guided PCI was noninferior to IVUS-guided PCI for 12-month target-vessel failure (4.1% vs 4.6%) in 1,105 patients.

Source:

https://www.tctmd.com/news/ccta-noninferior-ivus-pci-guidance-p4-trial

[Other] TCT 514 (1 Nov): fully automated deep-learning CT sizing as a pre-procedural check for paravalvular leak in TAVR.

Source:

https://www.tctmd.com/slide/tct-512-continuous-rcs-modeling-tavr-oversizing-mapping-non-linear-dose-response-between

5. Cardiology News

Structural Heart News:

[Abbott] VERITAS (TCT, 1 Nov): Amulet 360 LAA occluder at 1 year in 458 AF patients showed 96.3% complete closure, 1.8% stroke or systemic embolism and no device embolisation.

Source:

https://www.acc.org/latest-in-cardiology/articles/2026/11/01/00/11/sun-551pm-combo2-tct-2026

[Other] TRIC-I-HF-DZHK24 subgroups (TCT, 1 Nov): transcatheter tricuspid repair plus OMT beat OMT alone (win ratio 2.24), with and without prior HF hospitalisation.

Source:

https://www.acc.org/Latest-in-Cardiology/Articles/2026/11/01/00/11/sun-627pm-combo3-tct-2026

Coronary Interventions:

[Other] TRANSFORM II (TCT, 1 Nov): sirolimus-coated balloon was noninferior to everolimus DES in de novo coronary lesions (2.1% vs 2.4%).

Source:

https://cardiovascularnews.com/tct-2026-transform-ii-shows-non-inferiority-of-sirolimus-balloon-in-coronary-de-novo-lesions/

[Other] CELEBRATE (TCT, 31 Oct): zalunfiban at first medical contact for suspected STEMI kept its advantage to 1 year, with death or HF 9.3% vs 10.3% and less acute stent thrombosis.

Source:

https://www.tctmd.com/news/zalunfiban-advantage-suspected-stemi-lasts-1-year-celebrate

Devices: Nothing new this run.

Electrophysiology:

[Other] Q-INDEX randomised trial (Heart Rhythm, Oct): three very-high-power short-duration RF strategies for PVI in 150 paroxysmal AF patients.

Source:

https://www.heartrhythmjournal.com/article/S1547-5271(26)02811-0/abstract